Daiichi Sankyo and UMN Pharma collaborate over norovirus vaccine

14 February 2014
daiichi-sankyo-logo-big

Japanese drug companies Daiichi Sankyo (TYO: 4568) and UMN Pharma (TSE: 4585) have signed a collaborative research agreement for norovirus vaccine.

In the Immunization and Vaccine Committee the Health Science Council of Japan’s Ministry of Health, Labor and Welfare, held in December 2013, norovirus vaccine was selected as one of the vaccines with a high development priority.

Under the terms of the agreement, UMN Pharma will provide Daiichi Sankyo with recombinant norovirus virus-like particle (VLP) antigen which has been produced by a cell-culture manufacturing method employing the Baculovirus expression vector system (BEVS), a unique next-generation technology platform for manufacturing biopharmaceutical products. Daiichi Sankyo will conduct a basic research to determine the possibility to develop norovirus vaccine with a novel device.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical